Search results for "guideline"

showing 10 items of 800 documents

EFSUMB Guidelines 2011: Comment on Emergent Indications and Visions

2012

The focus of this article is the emergent and potential indications of contrast-enhanced ultrasound (CEUS). Emergent applications of CEUS techniques include extravascular and intracavitary contrast-enhanced ultrasound, quantitative assessment of microvascular circulation for tumor response assessment, and tumor characterization using dynamic contrast-enhanced ultrasound (DCE-US). Potential indications for microbubble agents include novel molecular imaging and drug and gene delivery techniques, which have been successfully tested in animal models. "Comments and Illustrations of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Non-Liver Guidelines 2011" whi…

medicine.medical_specialtyBlood Volumebusiness.industryUltrasoundContrast MediaReproducibility of ResultsProgramming LinearImage EnhancementTumor responseSensitivity and SpecificityRegional Blood FlowImage Interpretation Computer-AssistedPractice Guidelines as TopicQuantitative assessmentHumansMedicineRadiology Nuclear Medicine and imagingMedical physicsRadiologybusinessSocieties MedicalSoftwareUltrasonographyUltraschall in der Medizin - European Journal of Ultrasound
researchProduct

Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study

2010

Standard treatment of patients with breast cancer decreases with age and older persons are mostly excluded from clinical trials. We hypothesized that non-adherence to treatment guidelines occurs for women agedor =70 years and changes overall survival (OAS) and disease-free survival (DFS).We enrolled 1922 women agedor =50 years with histologically confirmed invasive breast cancer treated at the University of Ulm from 1992 to 2005. Adherence to guidelines and effects on OAS and DFS for women agedor =70 years was compared with that for younger women (50-69 years).Women70 years less often received recommended breast-conserving therapy (70-79 years: 74%-83%;79 years: 54%) than women agedor =69 y…

medicine.medical_specialtyBreast NeoplasmsMedical OncologyCohort StudiesBreast cancerGermanyInternal medicinemedicineHumansMastectomySurvival analysisAgedAged 80 and overGynecologyRadiotherapybusiness.industryStandard treatmentCarcinomaHazard ratioAge FactorsCancerProfessional PracticeHematologyMiddle Agedmedicine.diseaseSurvival AnalysisChemotherapy regimenOncologyChemotherapy AdjuvantFemaleGuideline AdherenceBreast diseasebusinessCohort studyAnnals of Oncology
researchProduct

The impact of psychopharmacology on contemporary clinical psychiatry.

2014

Clinical psychiatric evaluations of patients have changed dramatically in recent decades. Both initial assessments and follow-up visits have become brief and superficial, focused on searching for categorical diagnostic criteria from checklists, with limited inquiry into patient-reported symptomatic status and tolerability of treatments. The virtually exclusive therapeutic task has become selecting a plausible psychotropic, usually based on expert consensus guidelines. These guidelines and practice patterns rest mainly on published monotherapy trials that may or may not be applicable to particular patients but are having a profound impact, not only on modern psychiatric practice but also on…

medicine.medical_specialtyCanadaQuality Assurance Health CarePsychopharmacologyAlternative medicineMEDLINEpsychiatric treatmentspsychiatric diagnosisclinical psychiatryPsychiatric educationMedicineHumansPractice Patterns Physicians'PsychiatryRandomized Controlled Trials as TopicPsychiatryClinical psychiatryPsychotropic DrugsPractice patternsbusiness.industryMental DisordersExpert consensusChecklistPsychiatry and Mental healthTreatment OutcomeTolerabilityIn ReviewPsychopharmacologyClinical CompetenceGuideline AdherencebusinessForecastingCanadian journal of psychiatry. Revue canadienne de psychiatrie
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission in…

2019

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its con…

medicine.medical_specialtyCardiologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMaintenance Chemotherapy03 medical and health sciencesRemission induction0302 clinical medicineMaintenance therapymedicineHumans030212 general & internal medicineMedical prescriptionIntensive care medicineSocieties Medical030203 arthritis & rheumatologybusiness.industryRemission InductionGranulomatosis with PolyangiitisGeneral Medicinemedicine.diseaseBiological TherapyPractice Guidelines as TopicRituximabFranceGranulomatosis with polyangiitisbusinessMicroscopic polyangiitisVasculitisMepolizumabImmunosuppressive Agentsmedicine.drugLa Presse Médicale
researchProduct

Treatment of Tako-tsubo cardiomyopathy

2008

N.A.

medicine.medical_specialtyCardiotonic AgentsHeart diseasebusiness.industryCardiomyopathyTako-tsubo Cardiomyopathymedicine.diseaseTako-tsubo cardiomyopathyTakotsubo CardiomyopathyInternal medicinePractice Guidelines as TopicACE inhibitormedicineCardiologyHumansMyocardial diseaseCardiology and Cardiovascular MedicinebusinessBeta (finance)medicine.drugInternational Journal of Cardiology
researchProduct

Expert opinion on managing chronic HCV in patients with cardiovascular disease

2018

International audience; Extrahepatic manifestations of chronic HCV infection include cardiovascular diseases and an increase in cardiovascular mortality. The pathogenic mechanisms by which HCV contributes to cardiovascular disease are not well defined, however, it is likely that systemic inflammation, and the promotion of other metabolic diseases are involved. In this Review, the evidence for HCV infection as a non-traditional risk factor for cardiovascular disease is evaluated. Furthermore, practical advice to evaluate cardiovascular disease risk and disease in chronic hepatitis C patients are included for help in daily clinical practice. Despite the advances in therapies for the treatment…

medicine.medical_specialtyCardiotonic AgentsHepacivirusDisease030204 cardiovascular system & hematologySystemic inflammationAntiviral Agents03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesOdds RatioHumansMedicineDrug InteractionsPharmacology (medical)In patient030212 general & internal medicineRisk factorIntensive care medicineExpert TestimonyCardiovascular mortalityInflammationPharmacologybusiness.industryDisease progressionDisease ManagementHepatitis C Chronic3. Good healthInfectious DiseasesCardiovascular DiseasesExpert opinionPractice Guidelines as TopicDisease riskmedicine.symptombusiness
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Nurses' Use of Computerized Clinical Guidelines to Improve Patient Safety in Hospitals.

2015

Computerized clinical guidelines are frequently used to translate research into evidence-based behavioral practices and to improve patient outcomes. The purpose of this integrative review is to summarize the factors influencing nurses’ use of computerized clinical guidelines and the effects of nurses’ use of computerized clinical guidelines on patient safety improvements in hospitals. The Embase, Medline Complete, and Cochrane databases were searched for relevant literature published from 2000 to January 2013. The matrix method was used, and a total of 16 papers were included in the final review. The studies were assessed for quality with the Critical Appraisal Skills Program. The studies …

medicine.medical_specialtyCare processbusiness.industryMEDLINENursesPatient careHospitalsPatient safetyCritical appraisalFamily medicinePractice Guidelines as TopicmedicineHumansGuideline AdherencePatient SafetybusinessGeneral NursingWestern journal of nursing research
researchProduct

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (…

2017

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries

medicine.medical_specialtyCarotid artery diseasebusiness.industryAtherosclerotic diseaseUpper extremity artery diseaseGuideline030204 cardiovascular system & hematologyVascular surgeryLower extremity artery diseaseMultisite artery diseasePeripheral Arterial Diseases3. Good health03 medical and health sciences0302 clinical medicineRenal artery diseaseInternal medicinePeripheral arterial diseasemedicineCardiologyMesenteric artery disease030212 general & internal medicineVertebral artery diseaseCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct